The Efficacy of Whole-Course Local Simultaneous Integrated Boost Intensity-Modulated Radiotherapy in the Treatment of Locally Advanced Esophageal Cancer and Its Impact on Immune Function

Lei Yuan, Yujuan Gao

Show Less

¹ Tai’an Tumor Prevention and Treatment Hospital, Tai’an 271000, Shandong, China,

JCNR 2025 , 9(3), 224–230; https://doi.org/10.26689/jcnr.v9i3.10120

© 2025 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Abstract

Objective: To analyze the efficacy of whole-course local simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) on patients with locally advanced esophageal squamous cell carcinoma (ESCC). Methods: 88 patients with ESCC admitted to the hospital between October 2022 and October 2024 were selected and randomly divided into two groups using a random number table. The experimental group received SIB-IMRT treatment, while the control group received conventional intensity-modulated radiotherapy (C-IMRT). The objective remission rate, immune function, tumor markers, and adverse reaction rate were compared between the two groups. Results: The objective remission rate in the experimental group was higher than that in the control group (P < 0.05). Before treatment, there was no difference in immune function levels and tumor marker levels between the two groups (P > 0.05). After treatment, the immune function levels in the experimental group were better than those in the control group, and the tumor marker levels were lower than those in the control group (P < 0.05). The adverse reaction rate in the experimental group was lower than that in the control group (P < 0.05). Conclusion: SIB-IMRT can improve the objective remission rate of patients with ESCC, protect their immune function, down-regulate tumor marker levels, and prevent side effects after treatment.

References

Du F, Wang G, Wei Z, 2022, Clinical Study on Concurrent Chemotherapy with Intensity-Modulated Radiotherapy and S-1 or Capecitabine in the Treatment of Advanced Esophageal Cancer in Middle-Aged and Elderly Patients. Chinese Journal of Medicine, 57(4): 389–392.

Fu S, Jin W, Yu D, 2024, The Effect of Simultaneous Integrated Boost Intensity-Modulated Radiotherapy on Patients with Locally Advanced Esophageal Cancer. Chinese and Foreign Medical Research, 22(1): 117–120.

Zhang W, Ren L, Jiang C, et al., 2023, The Effect of Simultaneous Integrated Boost Intensity-Modulated Radiotherapy on Locally Advanced Esophageal Cancer and Its Impact on 3-Year Survival Rate. Clinical Misdiagnosis and Mistherapy, 36(1): 41–44.

Cao S, Zhang R, 2024, Effects of CT Simulation-Guided Three-Dimensional Conformal Intensity-Modulated Radiotherapy on Serum Tumor Markers and Quality of Life in Patients with Advanced Esophageal Cancer. Modern Medical Imaging, 33(1): 29–32.

Wang Y, 2024, Effects of Concurrent Chemotherapy and Intensity-Modulated Radiotherapy on Serum Tumor Marker Levels and Quality of Life in Patients with Advanced Esophageal Cancer. Reflexotherapy and Rehabilitation Medicine, 5(9): 149–151, 159.

Yang Y, Shao Y, Ma Z, et al., 2023, Effects of Intensity-Modulated Radiotherapy Combined with Chemotherapy on Imaging Findings and Quality of Life in Patients with Advanced Esophageal Cancer. Modern Medicine and Health Research (Electronic Edition), 7(8): 40–42.

Guo Q, Guo R, Li S, 2024, Efficacy of Simultaneous Integrated Boost Intensity-Modulated Radiotherapy in the Treatment of Locally Advanced Esophageal Cancer and Its Impact on Immune Function. Jilin Medical Journal, 45(11): 2703–2706.

Zhao Y, 2021, Clinical Application of Intensity-Modulated Radiotherapy Combined with Chemotherapy in the Treatment of Locally Advanced Non-Surgical Esophageal Cancer. Inner Mongolia Medical Journal, 53(7): 784–786.

Yu X, 2021, Clinical Study of Intensity-Modulated Radiotherapy Combined with Cisplatin and Paclitaxel Double-Drug Concurrent Chemotherapy in the Treatment of Locally Advanced Esophageal Cancer. Clinical Medicine, 41(1): 52–54.

Lan K, Guo R, Chen J, et al., 2024, Study on the Value of Endoscopic Titanium Clip Marking in Delineating the Target Volume During Radical Intensity-Modulated Radiotherapy for Patients with Unresectable Locally Advanced Esophageal Cancer. Chinese Journal of Medicinal Guide, 26(8): 808–813.

Xu X, Xing Y, Zhang L, et al., 2024, Effect of Micro-Adjustment Balance Prescription No.3 on the Efficacy of Intensity-Modulated Radiotherapy for Esophageal Cancer Patients. Naval Medical Journal, 45(6): 624–628.

Tai G, Wang G, Cui X, et al., 2024, Evaluation of the Efficacy of Simultaneous Integrated Boost Intensity-Modulated Radiotherapy and Sequential Radiotherapy in Cervical and Upper Thoracic Esophageal Cancer. Chinese Journal of Biomedical Engineering, 30(2): 130–134.

Wang H, Guo F, Che Y, et al., 2024, Study on the Deviation Between the Center of the Intensity-Modulated Radiotherapy Plan and the Center of the Target Volume in Esophageal Cancer. China Medical Equipment, 39(11): 44–50.

Shui M, Ye D, Wen J, et al., 2023, Effect and CT Findings of Intensity-Modulated Radiotherapy Combined with Chemotherapy in the Treatment of Esophageal Cancer. Journal of Molecular Imaging, 46(1): 83–87.

Guo N, Wang W, Wang Y, et al., 2022, The Impact of Simultaneous Integrated Boost Intensity-Modulated Radiotherapy on the Long-Term Prognosis of Patients with Cervical and Upper Thoracic Esophageal Cancer. Chinese Journal of Radiology and Protection, 42(1): 32–39.

Previous article in this issue

Next article in this issue